The results show that, compared with healthy controls, MAGI2-AS3 in PBMCs of breast cancer patients is significantly downregulated, which is consistent with its expression pattern in cancer tissues (Xue et al., 2021; Yang et al., 2018). Here, MAGI2 is linked to breast carcinoma.